Mayo Clinic liver and bile duct cancer program
Mayo Clinic Hepatobiliary SPORE
New treatments and tests to help people with liver and bile duct cancers (including hepatocellular carcinoma, cholangiocarcinoma, and fibrolamellar cancer) using immunotherapy, computer-driven biology, and targeted drug approaches.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11178572 on NIH RePORTER |
What this research studies
This Mayo Clinic program brings together clinicians, laboratory scientists, and data experts to move lab discoveries into patient care for liver and bile duct cancers. The work focuses on three cancer types—HCC, CCA, and fibrolamellar liver cancer—and runs projects using immunotherapy, computational biology, and chemical-genomic methods. Central cores provide bioinformatics and biostatistics support and help turn early ideas into clinical tools. An earlier project from this program produced a new drug that advanced into patient trials, and this renewal aims to expand those efforts.
Who could benefit from this research
Good fit: People diagnosed with hepatocellular carcinoma, cholangiocarcinoma, or fibrolamellar liver cancer who can enroll in clinical studies at Mayo Clinic would be ideal candidates.
Not a fit: People without liver or bile duct cancers, or those unable to travel to Mayo Clinic sites, are unlikely to be eligible or directly benefit from this program.
Why it matters
Potential benefit: Could lead to new, more effective and personalized treatments that improve survival and quality of life for people with hepatobiliary cancers.
How similar studies have performed: Related translational, immunotherapy, and precision-medicine approaches have shown promise, and this SPORE previously advanced a novel compound into clinical trials.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Mc Niven, Mark a. — Mayo Clinic Rochester
- Study coordinator: Mc Niven, Mark a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.